Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL28048151 | 0.88 | HCAR2 (0.40) | HCAR2CHRNB2CHRNA4ADORA2BADORA1 | |
| SCHEMBL20775371 | 0.82 | ADRB2 (0.46) | HCAR2CHRNB2CHRNA4IDH1CYP19A1 | |
| SCHEMBL16491297 | 0.82 | CYP11B2 (0.41) | HCAR2CHRNB2CHRNA4IDH1ADORA2B | |
| SCHEMBL17000186 | 0.82 | HCAR2 (0.36) | HCAR2CHRNB2CHRNA4IDH1CYP19A1 | |
| SCHEMBL28468744 | 0.82 | ADRB2 (0.46) | HCAR2CHRNB2CHRNA4IDH1CYP19A1 | |
| SCHEMBL725480 | 0.82 | PRMT5 (0.34) | GABRA1 | |
| SCHEMBL28361799 | 0.79 | PRMT5 (0.33) | GABRA1 | |
| SCHEMBL22585762 | 0.79 | HCAR2 (0.38) | HCAR2CHRNB2CHRNA4IDH1ADORA2B | |
| SCHEMBL22912527 | 0.79 | CYP11B1 (0.46) | HCAR2CHRNB2CHRNA4IDH1CYP19A1 | |
| SCHEMBL21779847 | 0.79 | CHRNB2 (0.35) | HCAR2CHRNB2CHRNA4IDH1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024126117-A1 | PYRIMIDINONE DERIVATIVES AS PESTICIDAL COMPOUNDS | BASF SE (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | HCAR2 2247/4885CHRNB2 1046/4885CHRNA4 1039/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | HCAR2 5/4885CHRNB2 933/4885CHRNA4 1024/4885 |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | HCAR2 261/4885CHRNB2 432/4885CHRNA4 242/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HCAR2 111/4885CHRNB2 40/4885CHRNA4 23/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | HCAR2 3697/4885CHRNB2 4832/4885CHRNA4 4647/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | HCAR2 279/4885CHRNB2 4864/4885CHRNA4 4668/4885 |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | ACE2, ACE, TMPRSS2 | HCAR2 3633/4885CHRNB2 4709/4885CHRNA4 4867/4885 |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | HCAR2 3448/4885CHRNB2 4343/4885CHRNA4 4799/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | HCAR2 1379/4885CHRNB2 4528/4885CHRNA4 4666/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | HCAR2 41/4885CHRNB2 121/4885CHRNA4 72/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | HCAR2 2141/4885CHRNB2 272/4885CHRNA4 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.